FDAnews
www.fdanews.com/articles/138477-biomarin-initiates-phase-i-trial-for-bmn-673-in-patients-with-advanced-hematological-malignancies

BioMarin Initiates Phase I Trial for BMN 673 in Patients with Advanced Hematological Malignancies

July 18, 2011
BioMarin Pharmaceutical announced the initiation of a Phase I trial for BMN 673, a poly ADP-ribose polymerase inhibitor, for the treatment of patients with advanced hematological malignancies. A Phase I/II trial for BMN 673 for the treatment of patients with solid tumors was initiated in January 2011 and is ongoing.
Bradenton Herald